Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHA223 > biotechnology > Flashcards

biotechnology Flashcards

1
Q

What is biotechnology?

A

the use of biological systems to generate useful products

uses endogenous biochemical pathways to drive product formation

can use genetic engineering and gene transfer technologies to augment biochemical pathways (to up/down regulate gene expression)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

biotechnology and pharmacy

A

the rising use of biologics

% of biologics on the market

  • 12% in 2004
  • 45% today
  • 60% by 2024
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the central dogma of molecular biology?

A
  • DNA in nucleus with genetic material
  • transcription creates a copy of a gene in the form of RNA
  • RNA read by ribosomes and the therapeutic protein is made
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is a promoter?

A

it switches on genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What switches off genes?

A

promoter at the 5’ end

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is removed when mRNA is made in eukaryotic cells?

A

introns

-> not in prokaryotic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How are proteins transported inside the cell?

A

in vesicles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What cuts DNA?

A

restriction enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do ligase enzymes do?

A

stick pieces of DNA back together

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What do restriction enymes do?

A

cut DNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What sticks DNA back together?

A

ligase enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is transformation in genetic engineering?

A

process of putting a piece of DNA inside a cell and cells grow and produce protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What allows cells to replicate in the expression vector?

A

origin of replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

benefits of using prokaryotyes

A
  • high growth rates
  • can be grown relatively cheaply
  • can be modified through genetic engineering easily
  • can generate a lot of product
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are eukaryotes used for?

A

to make more specalised/complex products like mAb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

eukaryotic expression systems that can be used

A
  • CHO (Chinese hamster ovary cell)
  • yeasts
  • plants/tobacco
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

eukaryotic expression systems that can be used

A
  • CHO (Chinese hamster ovary cell
  • yeasts
  • plants/tobacco
17
Q

When are CHO cells used?

A

mammalian proteins

18
Q

benefits with using yeast cells

A

can generate >500 g/L of culture

19
Q

What are plant/tobacco cells used for?

A

generate simple proteins (vaccines)

genetics and high expression is a problem

20
Q

What is removed from pro-hormone insulin (pre-pro-insulin) to give active insulin?

A 
signal peptide (AA 1-24)
C peptide (AA 57-87)
21
Q

chains in active insulin

A

A and B chain

22
Q

What part of insulin is removed in the ER?

A

signal peptide

gives pro-insulin

23
Q

Where are the 3 disulfide bonds in insulin?

A

2 holding A and B chain together

1 internal on A chain

24
Q

How is insulin formulated?

A

as a hexamer binded by Zn ion

-> 6 insulin monomers

25
Q

steps to purify insulin

A
  1. shake flask
  2. production fermenter
  3. cell harvest - centrifugation
  4. cell breakage - homogenisation
  5. chromotographic separation
  6. concentration and formuation
  7. final product
26
Q

insulin processng complexities

A
  • expression in host
  • expression format
  • expression level
  • expression strength
  • impurities - host cell proteins/lipids/DNA/carbs
  • removal of C peptide
  • what is the dosage?
  • formulation buffer?
  • stability of formulated material
27
Q

problems with liquid formulations

A

there can be some insoluble/soluble intermediates generated before or during formulation

28
Q

considerations for biological formulations

A

pH
temperature
antimicrobial requirements
bioavailability modulation

29
Q

process for formulation of liquid proteins

A

untrafiltration and diafiltration

UF/DF

30
Q

ultrafiltration (UF/DF)

A
  • insulin solution flows into filter
  • filter allows molecules of a certain size through
  • into permeate solution
  • the membrane has a sepcific Mr cut off measured in kDa
  • anything too big to pass through filter is put back into the starting material
  • volume of starting material will dec but the protein conc increases
30
Q

ultrafiltration (UF/DF)

A

insulin solution flows into filter

filter

31
Q

diafiltration (UF/DF)

A
  • volume of container (with protein) is kept the same
  • buffer is fed in at the same vol it goes out
  • 5-7 diavolumes of buffer exchanges (5-7x more of permeate)
32
Q

formulation of buffer during DV in inuslin formation

A
  • phosphate buffer pH 7.4
  • glycerol
  • m-cresol (excipient, anti-microbial and stabilises the protein)
33
Q

problems in the expression/fermentation stage

A

amino acid substitution
misfolds
truncates - half the protein produced

34
Q

problems in the purification process

A

pass through of impurities into the final formulation

-> buffers, resins, detergents, enzymes

35
Q

What is used to allow AA to be swapped/changes in insulin formulations?

A

recombinant DNA technology

36
Q

What controls the bioavailability of insulin?

A

the stability of the dimer association

-> 3 dimers of insulin make up the hexamer

37
Q

lispro

A

less stable dimer association -> disassociates easier

38
Q

conformations of the N terminus of the B chain of insulin

A

R state - relaxed, helix is fully extended by residues B1-B8

T state - taut, residues B1-B8 are are in an extended conformation, conserves alpha-helix of residues B9-B19

I state - intermediate between T and R states

-> in the hexamer dimers can be T6, R6 or T3R3

39
Q

wild type vs Lispro

A

WT - 4 H bonds stabilise T:Rf dimers, van der Waals interactions also, shallow cleft betwee the B chains, tight association

Lispro - swap of Lys and Pro removes some van der Waal interactions, cleft is slightly wider between the 2 monomers, less association between the monomers so it will quickly disassociate in blood with the pH change

40
Q

learning from early biological therapeutical development

A
  1. biologics are very specific for biological targets if they’re generated correctly
  2. systems used to generate biologics needs to be controlled/characterised to ensure correct product formulation
  3. recombinant DNA technologies allow generation of complex biological therapies
  4. once DNA sequence controlled, have control over protein structure, 1st gen to 2nd gen shorter time
  5. biological systems give product variability and product related impurities
  6. protein based drugs are stable if treated correctly, storage/use
  7. biologics can induce an immune response in a patient - wanted/unwanted

PHA223 (43 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions